Dangerous new pathogens such as the Ebola virus invoke scary scenarios of deadly epidemics, but even ancient scourges such as the bubonic plague are still providing researchers with new insights on how the body responds to infections.
In a study published online Sept. 18, 2014, in the journal Immunity, researchers at Duke Medicine and Duke-NUS Graduate Medical School Singapore detail how the Yersinia pestis bacteria that cause bubonic plague hitchhike on immune cells in the lymph nodes and eventually ride into the lungs and the blood stream, where the infection is easily transmitted to others.
The insight provides a new avenue to develop therapies that block this host immune function rather than target the pathogens themselves – a tactic that often leads to antibiotic resistance.
"The recent Ebola outbreak has shown how highly virulent pathogens can spread substantially and unexpectedly under the right conditions," says lead author Ashley L. St. John, PhD, assistant professor, Program in Emerging Infectious Diseases at Duke-NUS Singapore. "This emphasizes that we need to understand the mechanisms that pathogens use to spread so that we can be prepared with new strategies to treat infection."
While bubonic plague would seem a blight of the past, there have been recent outbreaks in India, Madagascar and the Congo. And it's mode of infection now appears similar to that used by other well-adapted human pathogens, such as the HIV virus.
In their study, the Duke and Duke-NUS researchers set out to determine whether the large swellings that are the signature feature of bubonic plague – the swollen lymph nodes, or buboes at the neck, underarms and groins of infected patients – result from the pathogen or as an immune response.
It turns out to be both.
"The bacteria actually turn the immune cells against the body," says senior author Soman Abraham, PhD, a professor of pathology at Duke and professor of emerging infectious diseases at Duke-NUS. "The bacteria enter the draining lymph node and actually hide undetected in immune cells, notably the dendritic cells and monocytes, where they multiply. Meanwhile, the immune cells send signals to bring in even more recruits, causing the lymph nodes to grow massively and providing a safe haven for microbial multiplication."
The bacteria are then able to travel from lymph node to lymph node within the dendritic cells and monocytes, eventually infiltrating the blood and lungs. From there, the infection can spread through body fluids directly to other people, or via biting insects such as fleas.
Abraham, St. John and colleagues note that there are several potential drug candidates that target the trafficking pathways that the bubonic plague bacteria use. In animal models, the researchers successfully used some of these therapies to prevent the bacteria from reaching systemic infection, markedly improving survival and recovery.
"This work demonstrates that it may be possible to target the trafficking of host immune cells and not the pathogens themselves to effectively treat infection and reduce mortality," St. John says. "In view of the growing emergency of multi-resistant bacteria, this strategy could become very attractive."
In addition to Abraham and St. John, study authors include W. X. Gladys Ang, Min-Nung Huang, Christian Kunder, Elizabeth W. Chan, and Michael D. Gunn.
The National Institutes of Health funded the study (R01 AI35678, R01 DK077159, R01 AI50021, R37 DK50814 and R21 AI056101).
Source: Duke Medicine
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.